The study of developmental trajectories is where epigenetics truly shines. The ''epi'' in epigenetics captures the fact that although epigenetic processes also preside over the maintenance and termination of gene expression, the unfolding and remodeling of chromatin architecture (the stuff of which epigenetics is made) are especially critical to prepare genes for regulated transcription. Indeed, epigenetic studies typically (but not exclusively) focus on what needs to happen for a cell or a tissue to become ''poised'' to express a given set of genes; those genes are still silent, but they are getting ready to go. This ''getting ready to go'' implies being on a path, a trajectory to events that will occur later thanks to epigenetic programming. Thus epigenetics is very much about timed and timely events, and epigenetic processes are the (almost invisible) puppeteer behind gene transcription.
EPIGENETIC PREDICTORS OF CHILDHOOD ASTHMA AT BIRTH
The elegant work on perfectly timed waves of epigenetic events that sweep through the T H 2 cytokine locus to allow regulated expression of IL-5, IL-13, and IL-4 in T cells 1 eloquently illustrates the power of basic epigenetic research to highlight fundamental biological trajectories. Unfortunately, leveraging that power for population studies in the asthma and allergy field is difficult for both logistical and technical reasons.
Most population studies are cross-sectional. Bringing epigenetics into such studies might provide interesting insight into the pathogenesis of concurrent disease but might also fall into the cause/effect trap: If epigenetic differences are detected between cases and control subjects, are they a cause or an effect of the disease? Much preferable are longitudinal approaches that, relying on the unique ability of epigenetic processes to shape temporal trajectories, allow exploration of the relationship between a given pattern of epigenetic remodeling (DNA methylation or histone modifications) in early life and the subsequent emergence of the phenotype of interest.
Our recent work on childhood asthma epigenetics in the Infant Immune Study (IIS), an unselected birth cohort closely monitored for asthma for more than 10 years, testified to the power of this approach by establishing a nexus between the immune epigenome at birth and asthma in the first decade of life. Indeed, we showed that neonates with asthma by 9 years of age carried DNA methylation profiles in their cord blood mononuclear cells that were distinct from those of neonates who did not become asthmatic. 2 Some of these results were especially significant. Our initial epigenome-wide analysis found almost 600 regions that were differentially methylated in IIS children who did and did not have asthma by age 9 years. When we constructed networks to elucidate the functional connections among these differentially methylated genomic regions, we found that a region in the SMAD family member 3 (SMAD3) promoter was the most connected node within the network. of Asthma Study) showed that SMAD3 promoter methylation at birth was selectively and significantly increased in asthmatic children of asthmatic mothers and was associated with childhood asthma risk. These findings provided the first evidence that the trajectory to childhood asthma might begin at birth with epigenetic modifications that cluster primarily in the SMAD3 pathway and are influenced by asthma in the child's mother.
It is noteworthy that SMAD3 is a well-replicated asthma-associated gene from genome-wide association studies (GWASs) 3, 4 and a master regulator of TGF-b-dependent signaling. In this capacity, SMAD3 is uniquely positioned to affect the trajectory to and pathogenesis of childhood asthma. Indeed, TGF-b controls the differentiation of regulatory T (Treg) and T H 17 cells; altered Treg and T H 17 cell activities have been reported in patients with childhood asthma, 5 and conversely, maternal exposure to asthmaprotective environments, such as farms, has been shown to activate the Treg cell compartment 6 and influence the expression of T H 17 markers. 7 On the other hand, SMAD3 and all 3 TGF-b isoforms are expressed at high levels during early lung development and are critical to ensure normal branching morphogenesis, epithelial cell differentiation, and maturation of surfactant synthesis. 8 The identification of SMAD3 as an epigenetic predictor of childhood asthma at birth suggests that the early epigenetic trajectory to asthma involves processes at the intersection between immune regulation and lung development.
GOING ONE STEP BACKWARD: MATERNAL INFLUENCES ON CHILDHOOD ASTHMA RISK
The detection of asthma-associated differential epigenetic programming already at birth is consistent with the possibility that asthma might have its origins in utero, a hypothesis supported by the finding that maternal history of asthma is the strongest risk factor for asthma in the child. 9 Further evidence for the in utero origins of asthma comes from associations of childhood asthma with other maternal prenatal conditions and exposures, such as maternal age, smoking, infectious illness, stress, weight gain, and exposure to farm animals. [10] [11] [12] To better understand maternal prenatal influences on the child's trajectory to asthma, we relied again on the IIS population to explore the relation between maternal immune status during pregnancy and asthma risk in the child. We found that the maternal profiles of cytokine production during the third trimester of pregnancy predict asthma in the child. More specifically, there was a strong inverse association between maternal production of IFN-g relative to IL-13 and IL-4 and asthma risk in the child's first decade of life. Interestingly, this relationship was found for prenatal but not postnatal maternal cytokine levels, was evident in children of nonasthmatic but not asthmatic mothers, and held for maternal but not paternal cytokines. Moreover, this relationship was independent of childhood allergy. 13 Although, to our knowledge, our study provided the first identification of a maternal prenatal immune indicator of subsequent asthma risk for children born to nonasthmatic mothers, the underlying mechanisms remained to be determined. Therefore, as a logical follow-up to our previous study of neonates, 2 we asked whether the relationship between maternal immune profiles during pregnancy and childhood asthma involves the neonatal epigenome and, if so, whether it differs in children of nonasthmatic and asthmatic mothers.
We performed a genome-wide survey of DNA methylation in cord blood mononuclear cells from 32 IIS neonates (19 with nonasthmatic mothers and 13 with asthmatic mothers). The maternal prenatal immune profile was defined as the ratio of IFN-g and IL-13 released in the supernatants of maternal mitogen-stimulated PBMCs isolated during the third trimester of pregnancy. Because of our previous findings, 2 associations between the log 10 -transformed prenatal IFN-g/IL-13 ratio and DNA methylation at individual neonatal CpG sites were assessed by using linear regression separately in children of asthmatic and nonasthmatic mothers. We found that levels of DNA methylation at 553 CpG sites were associated significantly with the prenatal maternal cytokine ratio in children of nonasthmatic mothers, whereas no significant association was detected in children born to asthmatic mothers. Of particular interest was the finding that the neonatal CpG sites associated with the maternal IFN-g/IL-13 ratio clustered predominantly in the retinoic acid receptor and aryl hydrocarbon receptor pathways and had TGF-b1 (TGFB1) as a prominent upstream regulator. 14 Although not definitive, these data suggest that the prenatal immune milieu influences epigenetic profiles at birth in ways that depend on maternal asthma status and primarily affects genes involved in the response to environmental cues. Moreover, our results point to an intriguing convergence among the epigenetic pathways that link maternal immune status, the neonatal methylome, and development of asthma during childhood. Indeed, TGFB1 and SMAD3 are part of a single signaling pathway that regulates both lung development and immune responses and in this capacity might modulate the inception and unfolding of the trajectory to childhood asthma. Finally, we note that runtrelated transcription factor 3 (RUNX3), another gene in the TGF-b pathway, was also found to be differentially methylated in peripheral blood immune cells when comparing inner-city children with persistent atopic asthma and healthy control subjects. 15 
EPIGENETICS, GENETICS, AND THE LINK BETWEEN CHILDHOOD ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
The trajectory to lung disease might not end in early life and might not stop at asthma. More and more attention focuses on the possibility that chronic obstructive pulmonary disease (COPD), a condition that currently claims more victims than any other disease except cancer and cardiovascular illnesses, might have its origins in early life thanks to its complex relationships with reduced lung function and childhood asthma. 16 Children with persistent asthma have been consistently shown to reach a lower FEV 1 plateau during the third decade of life than children without asthma. 17 Only a fraction of children with asthma go on to have fixed airflow limitation, but those who do typically proceed through 3 phases. 5, 16 Children with persistent asthma have a slightly but significantly lower maximal expiratory flow and respiratory system compliance shortly after birth than those without asthma, 18 suggesting that impaired lung growth in utero predisposes to the development of asthma. By the time they reach early school age, these children already have a large percentage of the deficits in FEV 1 that they will show during the plateau phase of lung function, 19 which suggests that the period between birth and age 6 years is critical for the development of airflow limitation in patients with persistent asthma. Further decreases in FEV 1 occur during the school years 20 and J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 in adult life as part of the natural history of asthma, but these decreases seem to account for a much smaller fraction of the total impairment than those observed in early life. 16 As a result of these deficits in FEV 1 growth, by the third decade of life, approximately 17% of all patients with mild or moderate asthma reach stage 1 COPD (postbronchodilator FEV 1 /forced vital capacity [FVC] ratio <0.70 and FEV 1 > _80% of predicted value), and 5% reach stage 2 COPD (postbronchodilator FEV 1 /FVC ratio <0.70 and FEV 1 <80% of predicted value). Overall, multidecade follow-ups in several cohorts around the world demonstrate that a history of asthma confers a 10-to 30-fold risk of COPD, with patients who experience reduced maximum growth of FEV 1 in early adulthood being at risk for early or more severe disease. 21 The possibility that, at least in some patients, asthma and COPD might represent temporal stages within a continuum of disease has led some to propose a new entity: the asthma-COPD overlap syndrome. 22 Although the criteria to diagnose this syndrome and even its existence as a separate entity are still debated, 23, 24 the intertwining of asthma in childhood, deficits in lung function growth, and COPD later in life is increasingly recognized. The underlying mechanisms are not understood. Airway biopsy specimens from infants with recurrent wheeze show no evidence of airway remodeling, but incipient thickening of the reticular basement membrane in mediumsized bronchi can be observed in preschool children with wheezing at approximately the age at which the largest deficits in airway growth appear in children with subsequent persistent asthma. 16 Not much is currently known about the role of altered airway development and immune function in these trajectories, but it is tempting to speculate that because of its unique positioning at the intersection of lung development and immune regulation, epigenetic (or genetic) modifications in the TGF-b pathway might provide a mechanistic link between asthma in early life and COPD in later years. Unfortunately, because patients with a COPD phenotype are typically excluded from asthma cohorts and few populations have been monitored long enough to cover the temporal unfolding of the childhood asthma-COPD trajectory, we cannot assess whether peculiar DNA methylation profiles characterize the neonatal epigenome in patients with asthma in the first years of life who are given a diagnosis of COPD later.
If epigenetics cannot currently illuminate the asthma-COPD trajectory, genetics might. COPD and lung function GWASs, which rely on large populations and well-powered meta-analyses, are providing tantalizing clues for a contribution of the TGF-b pathway to these phenotypes. In a 2011 study, TGFB2 was identified as a locus strongly associated with pulmonary function in a study of FEV 1 and FEV 1 /FVC ratio in 48,201 subjects of European ancestry, with follow-up of top associations in 46,411 additional subjects. 25 Soon thereafter, TGFB2 was found to be significantly associated with quantitative measures of emphysema and airway imaging phenotypes in the Genetic Epidemiology of COPD (COPDGene), Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE), National Emphysema Treatment Trial (NETT), and Genetics of COPD (GenKOLS) studies and with percentage gas trapping in the COPDGene study. 26 The year 2017 saw the publication of 3 distinct studies, all converging on the TGF-b pathway. The first study reported COPD-targeted analyses in 15,256 cases and 47,936 control subjects, followed by replication in 9,498 cases and 9,748 control subjects from the International COPD Genetics Consortium, and identified 22 genome-wide significant loci, including TGFB2. Thirteen novel genome-wide significant loci emerged from these analyses, and one of them was retinoic acid receptor b (RARB), which is also a member of the TGFB pathway (Fig 1).   2,14,15,25-30 The second study also focused on COPD and included 2,588 cases and 1,782 control subjects from 4 cohorts, combining results with existing data from 6,633 cases and 5,704 control subjects. The analysis of moderate-to-severe COPD confirmed signals in a number of previously identified loci, including TGFB2, and the analysis of severe COPD again found genomewide significant associations for TGFB2. The locus was also found to be associated with lung function. A variant in TGFB2 (rs4846480) was also part of a 7-gene genetic risk score constructed using genome-wide significant single nucleotide polymorphisms associated with COPD. This risk score was associated with a 1.86% reduction in FEV 1 percent predicted for each additional risk allele. 28 Finally, a study of 48,943 subjects selected from the extremes of the lung function distribution in UK Biobank, with follow-up in 95,375 subjects, found 97 independent signals for lung function. These signals tended to cluster in pathways related to development, elastic fibers, and epigenetic regulation and included several genes (TGFB2, GLIS family zing finger 3 [GLIS3], bone morphogenetic protein 2 [BMP2], and TGF-b receptor 3 [TGFBR3]) specifically belonging to the TGF-b pathway. 29 Of note, a recent GWAS examined current or former smoking non-Hispanic white subjects with COPD. Overlap subjects reported a history of physician-diagnosed asthma before the age of 40 years. A variant in SOX5 (rs59569785), which also related to TGFB pathway genes, was found to be associated with COPD and asthma overlap (Fig 1) . 30 
CONCLUSIONS
Unbiased epigenetic and genetic studies have the potential to identify biological pathways with a previously unrecognized role in underpinning the phenotypes of interest. The GWAS of asthma that pointed to genes in the epithelium/group 2 innate lymphoid J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 cell axis 3 provides an eloquent case in point. In this context it is noteworthy that epigenetic and genetic evidence from several independent studies of asthma, COPD, and lung function converge to highlight a potential role of the TGF-b pathway in these processes. These results raise the possibility that, at least in a subset of subjects, these conditions might be functionally connected in ways that need to be further defined but that likely reflect the uniquely pleiotropic nature of TGF-b pathway genes, particularly their ability to control both lung development and immune responses essential for regulation and inflammation. Therefore further characterization of this pathway in longitudinally phenotyped populations might unmask novel trajectories to lung disease that begin in utero and unfold into old age (Fig 2) .
